Polypharmacy
Conditions
Interventions
Patients randomized to participate in the intervention group will receive the Pharmacotherapy Review service, provided by pharmacists. Pharmaceutical interventions carried out during this service will
Sponsors
Fundação Universidade Federal de Sergipe
Fundação Universidade Federal de Sergipe
Eligibility
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: Be aged 60 years or older; Perform outpatient follow-up by physicians from the study site; Having systemic arterial hypertension, diabetes mellitus and/or dyslipidemia; Having uncontrolled blood pressure, glycemic and/or lipid levels; Taking medication for a period equal to or greater than three months for one of the chronic conditions of the study, these drugs being: losartan potassium together or not with other medications (systemic arterial hypertension), metformin together or not with other medications (diabetes mellitus), simvastatin together or not with other drugs (dyslipidemia); Included patients or caregivers must sign the Free and Informed Consent Form (TCLE)
Exclusion criteria
Exclusion criteria: Patients diagnosed with resistant or secondary systemic arterial hypertension; History of myocardial infarction or stroke in the last six months; Diabetes and/or secondary dyslipidemia; End-stage renal disease (glomerular filtration rate <10mL/min or hemodialysis); Liver disease; Cancer treatment; Acquired immunodeficiency syndrome or anticoagulation; Unstable psychiatric illness; If the patient is already followed up by other clinical pharmacists; Inability to attend scheduled appointments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome 1: Is related to Pharmacotherapy Complexity, which will be analyzed using the MRCI instrument (GEORGE et al., 2005; MELCHIORS et al., 2007). This instrument includes 65 items divided into three sections in which the following factors will be evaluated: section A (dosage forms present in pharmacotherapy), section B (dose frequency for each drug in pharmacotherapy) and section C (additional instructions, if present on medication). Each section will be evaluated individually, adding the result of the three sections to obtain the patient's individual MRCI.;Primary outcome 2: It is related to the clinical outcomes associated with health conditions that are a cardiovascular risk factor determined by the number of patients who will reach the therapeutic goals recommended for the clinical parameter(s) referring to each clinical condition established as an inclusion criterion. The parameters, as well as the therapeutic goals will be established according to Clinical Guidelines and Protocols. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome 1: It is related to the economic outcomes will be measured from the purchase and supply of medicines, emergency care, hospital admission and outpatient consultations. The reduction in the cost of supplying medicines will be raised from the withdrawal of unnecessary medicines, dose reduction, and/or exchange of medicine for another one of lower cost. The costs related to outpatient consultations, emergency care or hospital admission during the 12 months will be calculated between the control and intervention groups and also through the Procedures Table Management System - SIGTAP.;Secondary outcome 2: It is related to the results of resolution and prevention of pharmacotherapeutic problems comparing before and after pharmaceutical interventions. These problems will be classified in need, effectiveness, safety and adherence in order to solve pharmacotherapeutic problems (CIPOLLE et al., 2004). | — |
Countries
Brazil
Contacts
Public ContactFernanda Feitosa
Fundação Universidade Federal de Sergipe
Outcome results
None listed